Basilea to Develop ArQule's Cancer Candidate Derazantinib Worldwide Except China Region

Basilea Pharmaceutica International plans to develop and commercialize ArQule’s Phase III intrahepatic cholangiocarcinoma (iCCA) candidate derazantinib (ARQ087) worldwide except greater China, through an exclusive licensing agreement that ArQule said today could generate for it up to $336 million-plus.Derazantinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor now in a registrational trial ( NCT03230318 ) in patients with FGFR2 fusion-positive inoperable or advanced iCCA, a fo